Latest atopic dermatitis Stories
LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology.
CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat(TM) Kit.
The first study of its kind in the world â€” involving 336 children aged between six months and 16 years old â€” has shown that installing a water softener for three months brings no additional relief for eczema sufferers.
SAN FRANCISCO, Feb. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Oculus Innovative Sciences, Inc., (Nasdaq: OCLS) and maintains its $3.81 target price.
OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most potent...
Preventative tips may help minimize risks NEW ORLEANS, Feb.
New guidelines stress the need for proper diagnosis to confirm allergy NEW ORLEANS, Feb. 4, 2011 /PRNewswire-USNewswire/ -- Atopic dermatitis, one of the most common forms of eczema in this family of inflammatory skin diseases, is a chronic disease marked by red, cracked and itchy skin.
KVISTGARD, Denmark, February 1, 2011 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that it has completed a clinical Phase 2 trial of its smallpox vaccine, IMVAMUNE(R), in individuals suffering from atopic dermatitis (a.k.a. eczema).
Like a fence or barricade intended to stop unwanted intruders, the skin serves as a barrier protecting the body from the hundreds of allergens, irritants, pollutants and microbes people come in contact with every day.
LUXEMBOURG, December 15, 2010 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis. CT327 is a novel topically applied TrkA kinase inhibitor developed using the Creabilis' LSE (Low Systemic Exposure) technology.
- a meat pie that is usually eaten at Christmas in Quebec